coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Barrow Together PCN, Westmorland and Furness (LAD) · Health Inequalities Profile

    PCN U17992 · NHS Lancashire and South Cumbria Integrated Care Board · 8 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    59,563

    Registered population

    59.4% aged 18–64

    22.3%

    Aged 65+

    ICB 20.0% · England 17.9%

    1.9%

    Ethnic minority (non-White)

    0.8% Asian

    36.5%

    In IMD quintile 1

    ICB 30.6% · England 21.0%

    ~24,652

    Core20 residents (est.)

    Resident basis; registered basis ~22,352 · see page 3

    10,003

    Hypertension register

    +3.43% in 3 yrs · England +5.60%

    699

    SMI register

    31.7% of Westmorland and Furness (LAD)'s

    1,713

    COPD register

    Reviews +0.33% in 3 yrs

    Forecast to 2030

    11,175

    Hypertension patients, 2030

    +1,172 on today

    77.2%

    QRISK ≥20% on statins, 2030

    +4.59pp over 3 yrs

    4.8%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    1,546
    Unreviewed asthma patients alongside high youth prescribing.

    With 67.4% of 4,739 asthma patients reviewed and 2,512 items per 1,000 aged 5-19 (England 1,488), 1,546 lack reviews, which may reflect recall gaps.

    78.3%
    Frail diabetes and 80+ blood pressure lag.

    Frail diabetes HbA1c control is 78.3% (England 81.9%) and 80+ BP control is 79.7% (-2.4% vs England +2.2%), which may reflect review access.

    78.1%
    Strong statin and lipid-lowering therapy reach.

    Statin treatment in diabetes without CVD is 78.1% (+6.7% vs England +2.1%) and QRISK ≥20% lipid therapy is 67.0% (England 63.6%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65 and over make up 22.3% of registrations, exceeding England's 17.9%

    Barrow Together PCN serves 59,563 registered patients across member practices. Patients aged 65 and over comprise 22.3% (13,284 patients) of the list, below Westmorland and Furness LAD (25.9%), but above NHS Lancashire and South Cumbria ICB (20.0%) and England (17.9%). Adults aged 18–64 make up 59.4% (35,370) and those aged 0–17 represent 18.3% (10,909). Census resident data shows 98.2% White and 1.9% ethnic minority groups; area Census shares do not establish registered-patient ethnicity. An older age structure compared with England is consistent with higher demand for chronic disease management.

    Age profile

    0–1718.3%
    18–6459.4%
    65+22.3%

    65+: ICB 20.0%, England 17.9%

    Ethnicity

    White98.2%
    Asian0.8%
    Mixed0.5%
    Black0.4%
    Other0.2%

    Older people · falls rows are Westmorland and Furness (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Westmorland and Furness LA)1,5912,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)78.3%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)57.1%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Westmorland and Furness LA)7361,0219552024/25
    Falls deaths, all ages, per 100,000 (Westmorland and Furness LA)10.518.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 patients comprise 36.5% of the PCN, with an 82.2 pp practice range

    The PCN has 36.5% of registered patients in the Core20 most deprived quintile, above Westmorland and Furness LAD (9.2%), NHS Lancashire and South Cumbria ICB (30.6%) and England (21.0%). Deprivation spans an 82.2 pp range: The Family Practice has the highest concentration at 82.2% (2,318 estimated Core20 patients), while Duke Street Surgery has the highest volume with 4,699 estimated Core20 patients. Modelled weighted practice share (37.5%) differs from the PCN rate. Clinical outreach should prioritise high-concentration practices while administrative capacity addresses high-volume lists.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    The82.2% · 2,318 patients
    Atkinson48.5% · 3,184 patients
    Risedale46.3% · 3,315 patients
    Duke Street41.3% · 4,699 patients
    Bridgegate39.2% · 3,557 patients
    Norwood35.4% · 4,178 patients
    Abbey Road16.4% · 1,101 patients
    Burnett Edgar0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    699

    SMI register

    1.16% recorded prevalence

    422

    Learning disability register

    0.70% recorded prevalence

    11

    Care homes, 513 beds

    In the PCN catchment

    Severe mental illness prevalence is 1.2% (699 patients), against 0.9% in Westmorland and Furness LAD, 1.2% in the ICB and 1.0% in England. Learning disability prevalence is 0.7% (422 patients; comparators all 0.6%). Catchment care homes total 11 with 513 beds, though capacity does not confirm GP registrations. The SMI register is above the England rate, so physical-health checks for this group are the larger workload to protect.

    Severe mental illness: physical health checks

    On the SMI register (1.2% prevalence), 83.4% had a BP check (matching England 83.4%), while BMI recording was 79.8% (England 82.1%) and alcohol recording reached 77.7% (England 81.8%). Trailing physical check elements may leave cardiometabolic risks unmonitored.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    10,003

    Hypertension register

    +3.43%

    Register growth, 3 yrs

    Westmorland and Furness (LAD) +6.93% · England +5.60%

    +1.92pp

    BP control, under 80

    ≤140/90 · −1.93pp aged 80+

    +1,172

    More patients by 2030

    Forecast 11,175 (17.72%)

    Hypertension case-finding and control

    Hypertension prevalence is 16.6% (10,003 patients), above England (15.2%) but below Westmorland and Furness LAD (18.2%) and the ICB (17.2%). While blood pressure control for patients under 80 is 68.2% (England 67.8%), control at age 80+ is 79.7%, trailing England (81.2%), the LAD (81.5%) and the ICB (81.8%), having fallen 2.4% over 2023 to 2025 (England +2.2%). Recent blood pressure recording sits at 88.6% (England 90.0%). Older hypertensive patients trail national control benchmarks following a three-year decline, so prioritising dedicated blood pressure reviews for patients aged 80 and over is the key clinical opportunity.

    Lipids and statins

    Lipid-lowering therapy reaches 67.0% of patients with QRISK ≥ 20%, exceeding England (63.6%), Westmorland and Furness LAD (59.6%) and the ICB (61.4%). Statin coverage in diabetes without CVD is 78.1% (England 73.2%). With primary prevention lipid treatment exceeding all comparators, the PCN should sustain current initiation pathways across high-risk groups.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026139,764£1.90£1.64£1.86£265,552
    Cardiovascular (all), 2025195,236£3.20£3.38£3.33£624,755

    In 2026, lipid-modifying prescribing cost £1.90 per item across 139,764 items (£265,552 spend), above England (£1.86), Westmorland and Furness LAD (£1.68) and the ICB (£1.64). The PCN spent £36,339 more than at the ICB unit cost and £5,591 more than England. Higher unit spend than regional benchmarks suggests an opportunity to review lipid-modifying formulary choices across member practices.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +0.25%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.46%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 8.3% (4,739 patients; England 6.6%), and asthma management prescribing at ages 5-19 reaches 2,512 items per 1,000 (England 1,488; ICB 1,828). However, annual asthma review reach is 67.4% (LAD 70.4%), growing just +0.2% over three years (England +4.4%), leaving 1,546 patients unreviewed. Second-hand smoke recording for ages 6-19 is 75.7% (England 78.8%). Meanwhile, COPD prevalence is 2.8% (1,713 patients; England 1.9%), but fell 3.4% over three years (England +2.6%). High youth prescribing alongside review shortfalls could indicate uncontrolled asthma requiring proactive paediatric review.

    Cancer register and children's immunisation

    The cancer register records 2,628 patients (4.3% prevalence; England 3.8%, LAD 5.3%). In childhood immunisation, age-5 MMR1 achieves 96.6% (exceeding the 95.0% target), but MMR2 is 94.1% (a 2.5 pp difference), and the 4-in-1 pre-school booster reaches 90.7% (4.3 pp below the 95.0% target). While exceeding England (80.9%), lower pre-school booster coverage indicates a potential protection gap.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months95.7%

    England 91.0%

    6-in-1 complete primary course at 24 months92.1%

    England 92.2%

    MMR dose 1 at 24 months92.1%

    England 88.3%

    MMR dose 2 at age 594.1%

    England 82.8%

    4-in-1 pre-school booster at age 590.7%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    52.4%

    Lancashire and South Cumbria ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,010

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Lancashire and South Cumbria ICBEnglandNo usable stageStaged cancers
    Breast86.0%85.4%6%1,561
    Prostate42.4%53.2%11%1,404
    Lung31.1%33.8%15%1,374
    Bowel44.2%47.0%13%1,198
    Skin cancer86.1%87.8%21%519

    In 2022, NHS Lancashire and South Cumbria ICB diagnosed 52.4% of staged cancers at stage 1 or 2 (4,642 of 8,863 known-stage cases; 74.6% known-stage share), 22.6 pp below the 75.0% national ambition and trailing England (55.3%). Early-stage share fell 1.2 pp from 53.6% in 2013 (about 2,010 extra cases needed). In Barrow Together PCN, cervical screening at ages 25-49 is 66.5% (Westmorland and Furness LAD 72.2%), falling 4.9% over 2023 to 2025 (England -1.0%). The Family Practice recorded 54.2%, Norwood Medical Centre recorded 57.5%, and Risedale Surgery recorded 63.1%. Stage data reflects ICB geography, not PCN delivery. Lower cervical screening may delay early detection; practice recall audits would test.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At University Hospitals of Morecambe Bay NHS Foundation Trust, the 62-day cancer referral to treatment standard was 12.6 pp below the 85.0% standard. The trust was 3.4 pp above the 75.0% 28-day faster diagnosis standard and 0.8 pp below the 96.0% 31-day combined treatment standard. Across NHS Lancashire and South Cumbria Integrated Care Board, 62-day referral to treatment was 11.4 pp below the 85.0% standard. Barrow Together PCN cancer prevalence is 4.3% (2,628 patients); acute waits describe system context, not PCN delivery. Prolonged acute treatment waits may require robust PCN safety-netting while patients await definitive cancer therapy.

    Pathways within standard (%)of Morecambe BayBlackpoolLancashireLancashire and South Cumbria ICBEngland
    28-day faster diagnosis (75%)78.3971.3882.9078.3979.32
    31-day treatment (96%)95.2297.9689.4393.6292.50
    62-day referral to treatment (85%)72.3567.4875.0473.6271.16
    Diagnostic waits over 6 weeks (%)of Morecambe BayBlackpoolLancashireEngland
    MRI4.0421.802.4121.40
    CT13.7616.4914.979.92
    Echocardiography10.557.5713.8528.48
    Colonoscopy0.6013.080.0030.83
    Gastroscopy1.4512.470.0029.02
    All 15 DM01 tests10.4426.5426.6523.14
    Community services activityWestmorland and Furness residentsLancashire and South Cumbria ICB
    Care contacts53,485193,720
    Referrals6,47029,855
    Patients with a contact13,44565,335

    Community services (residents of Westmorland and Furness), Jun 2026 (provisional). In the provisional Community Services Dataset for Jun 2026, Westmorland and Furness residents recorded 53,485 community contacts, of which 36,330 (67.9%) were for adults aged 65 and over. These figures describe borough-wide activity rather than PCN performance. Substantial community use among older residents indicates an opportunity to coordinate primary care reviews with borough community nursing teams.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Vaccination and immunisation achievement varies across practices by 51.7 pp

    Across England, overall QOF achievement was 92.5% in 2025/26. Overall QOF achievement was 86.3% at Atkinson Health Centre, whereas it was 97.5% at Duke Street Surgery. Vaccination and immunisation-domain achievement varies by 51.7 pp between captured practices, recorded at 40.9% for The Family Practice and 92.6% for Risedale Surgery.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Abbey Road Surgery12616.489.2%77.0%87.9%
    Atkinson11048.573.1%82.4%86.0%
    Burnett Edgar1290.075.8%70.6%84.3%
    Duke Street14041.364.3%66.6%76.8%
    Bridgegate10839.259.2%63.8%72.6%
    Norwood10735.440.0%69.6%66.2%
    The9682.267.0%40.4%61.9%
    Risedale Surgery10646.354.1%73.7%59.1%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNWestmorland and Furness (LAD)AssetPCNWestmorland and Furness (LAD)
    Care homes (catchment)11 (513 beds)n/aSchools (catchment)64n/a
    Children's centres412Places of worship33316
    Libraries214Food banks (VCS)n/a2
    Day centres (VCS)n/a2Children and young people (VCS)n/a3
    Carers support groups (VCS)n/a2Primary schools (LA maintained)1482
    Primary academies1027Special schoolsn/a4

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review and inhaler recall

    Asthma review reach is 67.4% (+0.2% over 2023 to 2025 vs England +4.4%, LAD 70.4%), leaving 1,546 of 4,739 patients unreviewed alongside 2,512 items per 1,000 aged 5-19 (England 1,488). For discussion: run structured asthma recall using a shared template, offering after-school slots and reviewing inhaler prescribing. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Frailty diabetes and 80+ hypertension recall

    Frail diabetes HbA1c <=75 mmol/mol in 2024/25 is 78.3% (836 of 1,068; England 81.9%); BP <=150/90 mmHg at age 80+ is 79.7% (England 81.2%, LAD 81.5%), down 2.4% over 2023 to 2025. For discussion: run pharmacist-led recall and home or care-home medication reviews for frail diabetic and 80+ hypertensive patients. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school booster and MMR2 catch-up recall

    In Q1 2025/26 (cohort 120), age-5 4-in-1 coverage is 90.7% (4.3 pp below the 95.0% target) and MMR2 is 94.1% (2.5 pp below MMR1 at 96.6%), with a 51.7 pp QOF vaccination range. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older population review coordination (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Mental health physical check outreach (p4)SMI register with a BMI recorded in the last 12 monthsMHIS · From Harm to HopePCN
    Older hypertensive review audit (p5)Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · Structured asthma review and inhaler recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · Frailty diabetes and 80+ hypertension recall (p12)Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Pre-school booster and MMR2 catch-up recall (p12)4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN & Practice
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15